Prior Local or Systemic Treatment: A Predictive Model Could Guide Clinical Decision-Making for Locoregional Recurrent Breast Cancer

• DOI: 10.3389/fonc.2021.791995
• Publication Date: 2022-02-07T05:25:35Z
• Authors: Huai-liang Wu; Yu-jie Lu; Jian-wei Li; Si-yu Wu; Xiao-song Chen; Guang-yu Liu
• Keywords: Nomogram; Concordance; Systemic therapy

Locoregional recurrent breast cancer indicates poor prognosis. No solid prediction model is available to predict prognosis and guide clinical management. Prior local treatment or systemic remains controversial.Locoregional patients operated in Fudan University Shanghai Cancer Center were enrolled as a training cohort. An external validation cohort included after locoregional recurrence from Ruijin Hospital, Jiaotong University. A nomogram predicting overall survival was established using multivariable Cox regression analysis while internal performed evaluate its calibration discrimination.Overall, 346 96 the separately. developed, including age, neoadjuvant chemotherapy, surgery, pathology type, tumor size, lymph node status, hormonal receptor Her-2 disease-free interval, sites of recurrence. It had modest discrimination cohort, (concordance index: 0.751, 0.734 0.722, respectively). The classified 266 80 into low high-risk subgroups with distinctive Local associated improved low-risk group (P = 0.011), therapies correlated better outcomes only < 0.001).A based on clinicopathological factors can identify patients. prior choice for whereas needs be considered patients, warranting further exploration.